CAPS

Business Context and Reporting Period

Company: OrthoLogic Corp. (Note: Metadata listed "Capstone Holding Corp." but filing text confirms OrthoLogic Corp.)
Filing Type: Form 10-Q
Period Ended: June 30, 2001
Business Overview: OrthoLogic is a medical device company. During the quarter, the company exited its Continuous Passive Motion (CPM) business, which previously accounted for approximately two-thirds of its revenues. The CPM assets were sold in early July 2001. The company also terminated its co-promotion agreement for Hyalgan, transitioning to a royalty model.

Key Financial Metrics

Liquidity & Debt: As of June 30, 2001, the company held $11.6 million in cash and cash equivalents and $3.6 million in short-term investments. The company has no debt and no derivative instruments. It maintains a $10.0 million revolving line of credit (unused) which is currently under negotiation for a lower facility amount.

Material Changes vs. Prior Period

• Revenue Decline: Revenues decreased 1.8% in Q2 and 2.6% for the six months compared to 2000. This was driven by the termination of Hyalgan distribution and a 6.6% decline in CPM product sales.
• Non-Recurring Charges: The company recorded $14.3 million in "CPM divestiture and non-recurring charges" in Q2 2001. This includes a $6.9 million write-down of CPM assets, $3.3 million in severance for 331 employees, and other exit costs.
• Profitability Shift: The company swung from a net profit of $549,000 in Q2 2000 to a net loss of $14.986 million in Q2 2001. Management states that excluding one-time CPM divestiture costs and a $1.0 million Chrysalin license charge, the company would have earned $341,000 in Q2 2001.
• Asset Reduction: Total assets decreased from $65.0 million (Dec 31, 2000) to $55.5 million (June 30, 2001), primarily due to the write-down of CPM assets held for sale and reduced inventory.

Guidance, Outlook, and Risks

• Outlook: Management anticipates that current cash balances, cash from operations, and the line of credit will be sufficient to meet requirements for the next 12 months. Future funding beyond 12 months depends on generating sufficient cash flow or obtaining additional financing.
• Strategic Focus: Post-CPM divestiture, the company is focusing on fracture healing and spine products, which saw a 47% sales increase in Q2 2001. The company is also advancing clinical trials for Chrysalin (a peptide for fracture healing) and expanding its license to include soft tissue indications.
• Litigation: The company reached a settlement regarding class action lawsuits filed in 1996. The settlement involves $1 million in cash and 1 million shares of common stock (valued at $2.97 million). While management believes the settlement is in the company's best interest, it remains subject to court and plaintiff approval.
• Risks: Key risks include the ability to collect receivables from the sold CPM business (retained by OrthoLogic), regulatory approval for new products (Chrysalin), and the impact of managed care on reimbursement rates.

Investor Verification Checklist

• CPM Receivables Collection: Verify the collectability of the $10.8 million in CPM-related receivables retained by OrthoLogic, as the original collection team was hired by the buyer.
• Chrysalin Milestones: Monitor the progress of Chrysalin Phase III clinical trials and the associated milestone payments required by the license agreement.
• Litigation Finalization: Confirm the final court approval of the $3.97 million class action settlement to ensure no further legal exposure.
• Line of Credit Terms: Review the revised terms of the $10 million revolving credit facility, as the company is negotiating a lower limit.
• Run-Rate Profitability: Assess the sustainability of the "adjusted" profitability ($341k Q2 earnings) once the one-time divestiture charges are removed, given the loss of the CPM revenue stream.